Designing multi-target drugs for the treatment of major depressive disorder.

Even though large variations were observed in the selection of pharmacological targets, some potential biological targets (NMDA, melatonin receptors) are required to be explored extensively for the design of MTDLs. Similarly, apart from structure activity relationship (SAR), in silico techniques such as multitasking cheminformatic modeling, molecular dynamics simulation and virtual screening should be exploited to a greater extent.